Regular paper
Psychostimulant-like effects of p-fluoroamphetamine in the rat

https://doi.org/10.1016/0014-2999(95)00478-5Get rights and content

Abstract

The present study was undertaken to compare the pharmacological properties of p-fluoroamphetamine with those of amphetamine and of other halogenated amphetamines, using several in vivo and in vitro tests. These included substitution testing in (+)-amphetamine (1 mg/kg, 5.4 μmol/kg, i.p.)-, (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine [(+)-MBDB] (1.75 mg/kg, 7.18 μmol/kg, i.p.)-, and 5-methoxy-6-methyl-2-aminoindan (MMAI) (1.71 mg/kg, 8 μmol/kg, i.p.)-trained rats, [3H]5-HT and [3H]dopamine uptake inhibition in whole brain synaptosomes, and changes in striatal extracellular levels of dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), and homovanillic acid (HVA) as measured by in vivo microdialysis in freely moving rats. In drug discrimination substitution tests, p-fluoroamphetamine fully mimicked (+)-amphetamine (ED50 0.43 mg/kg, 2.11 μmol/kg), whereas ‘no substitution’ was observed in rats traincd to discriminate the serotonin (5-hydroxytryptamine, 5-HT)-releasing agents (+)-MBDB or MMAI from saline. p-Chloroamphetamine did not substitute for amphetamine but fully substituted for the (+)-MBDB and MMAI cues (ED50 0.17 mg/kg, 0.82 μmol/kg, and 0.14 mg/kg, 0.69 μmol/kg, respectively), p-Fluoroamphetamine, in comparison with p-chloroamphetamine and p-iodoamphetamine, showed much stronger inhibition of [3H]dopamine than [3H]5-HT uptake into rat brain synaptosomes but was less selective than amphetamine. p-Fluoroamphetamine (7.0 mg/kg, i.p.), 1 h after administration, strongly elevated (849% of baseline) extracellular dopamine in rat striatum measured using in vivo microdialysis. Amphetamine (2 mg/kg, i.p.) increased extracellular dopamine in rat striatum with a maximum at the same time as did p-fluoroamphetamine, but the latter gave a smaller increase. The data presented suggest that p-fluoroamphetamine resembles amphetamine more than it does the 5-HT-releasing type amphetamines.

References (50)

  • D.E. Nichols et al.

    5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine

    Pharmacol. Biochem. Behav.

    (1991)
  • A. Pletscher et al.

    Decrease of cerebral 5-HT and 5-hydroxyindoleacetic acid by an aryl alkyl amine

    Life Sci.

    (1963)
  • T. Sharp et al.

    p-Chloro-amphetamine releases both serotonin and dopamine into rat brain dialysates in vivo

    Neurosci. Lett.

    (1986)
  • T. Sharp et al.

    A direct comparison between amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis

    Brain Res.

    (1987)
  • R.S. Sloviter et al.

    Para-halogenated phenethylamines: similar serotonergic effects in rats by different mechanisms

    Pharmacol. Biochem. Behav.

    (1980)
  • T.D. Steele et al.

    Stereochemical effects of 3,4-methylene-dioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]-monoamines into synaptosomes from different regions of rat brain

    Biochem. Pharmacol.

    (1987)
  • R. Sugita et al.

    Effect of p-chloroamphetamine administration on monoamine metabolism in the rat nucleus accumbens and locomotor activity: studies with intracerebral dialysis in freely moving rats

    Brain Res.

    (1994)
  • B.J. Van Groll et al.

    Stimulus effects of d-amphetamine. 1: DA mechanisms

    Pharmacol. Biochem. Behav.

    (1992)
  • B.K. Yamamoto et al.

    A neurochemical heterogeneity of the rat striatum as measured by in vivo electrochemistry and microdialysis

    Brain Res.

    (1990)
  • L.G. Bergi et al.

    Structure-activity relationships in CF3 substituted phenethylamines

  • F.C. Colpaert et al.

    A drug discrimination analysis of the lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenpirone, a LSD-antagonist

    J. Pharmacol. Exp. Ther.

    (1982)
  • G.D. D'Mello et al.

    Comparison of the discriminative stimulus properties of cocaine and amphetamine in rats

    Br. J. Pharmacol.

    (1977)
  • S.I. Dworkin et al.

    6-Hydroxydopamine lesions of the nucleus accumbens attenuate the discriminative stimulus effects of d-amphetamine

    Drug Dev. Res.

    (1989)
  • R.W. Fuller

    Structure-activity relationships among the halogenated amphetamines

    Ann. NY Acad. Sci.

    (1978)
  • R.W. Fuller et al.

    Influence of ring and side substituents on the selectivity of amphetamine as a monoamine oxidase inhibitor

    Res. Commun. Subst. Abuse

    (1982)
  • Cited by (43)

    • Synthetic amphetamine derivatives, benzofurans, and benzodifurans

      2021, Novel Psychoactive Substances: Classification, Pharmacology and Toxicology
    • Identification and characterization of 4-chloromethamphetamine (4-CMA) in seized ecstacy — a risk to public health

      2018, Forensic Science International
      Citation Excerpt :

      Based on these in vivo rat data one might expect 4-CA to have about four times the potency of MDMA. Also, in a study performed in 1995 it was demonstrated that 4-CA is a more potent 5-HT uptake inhibitor than amphetamine or 4-fluoroamphetamine, although less potent at dopamine and norepinephrine reuptake sites [17]. 4-CMA is the N-methylated derivative of 4-CA and will be more lipophilic and hence more likely to penetrate the blood–brain barrier and potentially more potent in vivo than 4-CA itself.

    View all citing articles on Scopus
    a

    Present address: Department of Pharmaceutical and Biomedical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, OH 45810, USA.

    View full text